. Easl, Clinical Practice Guidelines: management of hepatitis C virus infection, J Hepatol, vol.60, issue.12, pp.392-420, 2014.

K. Kitrinos, A. Corsa, Y. Liu, J. Flaherty, A. Snow-lampart et al., No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B, Hepatology, vol.51, issue.2, pp.434-476, 2014.
DOI : 10.1002/hep.26686

T. Chang, C. Lai, K. Yoon, S. Lee, S. Coelho et al., Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B, Hepatology, vol.2, issue.Suppl. 1, pp.422-452, 2010.
DOI : 10.1002/hep.23327

J. Grennan, M. Loutfy, D. Su, P. Harrigan, C. Cooper et al., Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events Analysis, Journal of Infectious Diseases, vol.205, issue.8, pp.1230-1238, 2012.
DOI : 10.1093/infdis/jis104

A. Boyd, J. Gozlan, S. Maylin, C. Delaugerre, G. Peytavin et al., Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B Improving the measurement of self-reported medication nonadherence: response to authors, Hepatology Clin Infect Dis World J Gastroenterol J Clin Epidemiol, vol.605613864, pp.497-507, 2007.

R. Zoutendijk, J. Reijnders, A. Brown, F. Zoulim, D. Mutimer et al., Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of na??ve patients with a partial virological response, Hepatology, vol.49, issue.5 Suppl., pp.443-51, 2011.
DOI : 10.1002/hep.24406

H. Chan, C. Chan, A. Hui, S. Chan, F. Poordad et al., Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA, Gastroenterology, vol.146, issue.5, pp.1240-1248, 2014.
DOI : 10.1053/j.gastro.2014.01.044

A. Lok, H. Trinh, G. Carosi, U. Akarca, A. Gadano et al., Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Na??ve Patients With Chronic Hepatitis B, Gastroenterology, vol.143, issue.3, pp.619-647, 2012.
DOI : 10.1053/j.gastro.2012.05.037

A. Pozniak, R. Gupta, D. Pillay, J. Arribas, and A. Hill, Causes and Consequences of Incomplete HIV RNA Suppression in Clinical Trials, HIV Clinical Trials, vol.200, issue.292, pp.289-98, 2009.
DOI : 10.1097/01.aids.0000131332.30548.92

J. Reijnders, K. Deterding, J. Petersen, F. Zoulim, T. Santantonio et al., Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues, Journal of Hepatology, vol.52, issue.4, pp.493-500, 2014.
DOI : 10.1016/j.jhep.2010.01.012

A. Snow-lampart, B. Chappell, M. Curtis, Y. Zhu, F. Myrick et al., No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus, Hepatology, vol.51, issue.3, pp.763-73, 2011.
DOI : 10.1002/hep.24078

W. Chotiyaputta, C. Peterson, F. Ditah, D. Goodwin, and A. Lok, Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B, Journal of Hepatology, vol.54, issue.1, pp.12-20, 2011.
DOI : 10.1016/j.jhep.2010.06.016

W. Chotiyaputta, C. Hongthanakorn, K. Oberhelman, R. Fontana, T. Licari et al., Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs, Journal of Viral Hepatitis, vol.21, issue.3, pp.205-217, 2012.
DOI : 10.1111/j.1365-2893.2011.01494.x

P. Sogni, M. Carrieri, H. Fontaine, V. Mallet, A. Vallet-pichard et al., The role of adherence in virological suppression in patients receiving anti-HBV analogues, Antiviral Therapy, vol.17, issue.2, pp.395-400, 2012.
DOI : 10.3851/IMP1944

M. Hilleret, S. Larrat, F. Stanke-labesque, and V. Leroy, Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?, Journal of Hepatology, vol.55, issue.6, pp.1468-1477, 2011.
DOI : 10.1016/j.jhep.2011.04.006

J. Martinet, T. Dufeu-duchesne, B. Costa, J. Larrat, S. Marlu et al., Altered Functions of Plasmacytoid Dendritic Cells and Reduced Cytolytic Activity of Natural Killer Cells in Patients With Chronic HBV Infection, Gastroenterology, vol.143, issue.6, pp.1586-1596, 2012.
DOI : 10.1053/j.gastro.2012.08.046

U. Iloeje, H. Yang, J. Su, C. Jen, S. You et al., Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load, Gastroenterology, vol.130, issue.3, pp.678-86, 2006.
DOI : 10.1053/j.gastro.2005.11.016

V. Leroy and S. Kim, Can transient elastography be used for the management of chronic hepatitis B patients?, Liver International, vol.53, issue.4, pp.528-558, 2012.
DOI : 10.1111/j.1478-3231.2012.02768.x

P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert et al., Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study, The Lancet, vol.381, issue.9865, pp.468-75, 2013.
DOI : 10.1016/S0140-6736(12)61425-1

C. Meffre, L. Strat, Y. Delarocque-astagneau, E. Dubois, F. Antona et al., Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: Social factors are important predictors after adjusting for known risk factors, Journal of Medical Virology, vol.15, issue.4, pp.546-55, 2010.
DOI : 10.1002/jmv.21734

U. H. Iloeje, H. I. Yang, J. Su, C. L. Jen, S. L. You et al., Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load, Gastroenterology, vol.130, issue.3, pp.678-686, 2006.
DOI : 10.1053/j.gastro.2005.11.016

P. San-lin-you, M. Lu, . Phd-;-guan-tarn, M. Huang, H. Uchenna et al., Risk of Hepatocellular Carcinoma across a Biological Gradient of Serum Hepatitis B Virus DNA Level, JAMA, vol.295, issue.1, pp.65-73, 2006.

G. Paratheodoridis, S. Manolakopoulos, Y. Liaw, and A. Lok, Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review, Journal of Hepatology, vol.57, issue.1, pp.196-202, 2012.
DOI : 10.1016/j.jhep.2011.11.030

H. Chan, G. Wong, P. Choi, A. Chan, A. Chim et al., Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B, Journal of Viral Hepatitis, vol.13, issue.Suppl. 1, pp.36-44, 2009.
DOI : 10.1111/j.1365-2893.2008.01037.x

H. Janssen, Z. Van, H. Senturk, S. Zeuzem, U. Akarca et al., Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial, The Lancet, vol.365, issue.9454, pp.123-129, 2005.
DOI : 10.1016/S0140-6736(05)17701-0

C. Lai, R. Chien, N. Leung, T. Chang, R. Guan et al., A One-Year Trial of Lamivudine for Chronic Hepatitis B, New England Journal of Medicine, vol.339, issue.2, pp.61-68, 1998.
DOI : 10.1056/NEJM199807093390201

T. Chang, R. Gish, R. De-man, A. Gadano, J. Sollano et al., A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B, New England Journal of Medicine, vol.354, issue.10, pp.1001-1010, 2006.
DOI : 10.1056/NEJMoa051285

C. Lai, E. Gane, Y. Liaw, C. Hsu, S. Thongsawat et al., Telbivudine versus lamivudine in patients with chronic hepatitis B Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B, N Engl J Med N Engl J Med, vol.35717348, pp.2576-2588808, 2003.

P. Marcellin, E. Heathcote, M. Buti, E. Gane, R. De-man et al., Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B, New England Journal of Medicine, vol.359, issue.23, pp.2442-2455, 2008.
DOI : 10.1056/NEJMoa0802878

N. Tassopoulos, R. Volpes, G. Pastore, J. Heathcote, M. Buti et al., Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis BB, Hepatology, vol.27, issue.3, pp.889-896, 1999.
DOI : 10.1002/hep.510290321

P. Marcellin, G. Lau, F. Bonino, P. Farci, S. Hadziyannis et al., Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, vol.351, issue.12, pp.1206-1217, 2004.
DOI : 10.1056/NEJMoa040431

C. Lai, D. Shouval, A. Lok, T. Chang, H. Cheinquer et al., Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, vol.354, issue.10, pp.1011-1020, 2006.
DOI : 10.1056/NEJMoa051287

H. Mommeja-marin, Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature, Hepatology, vol.180, issue.6, pp.1309-1328, 2003.
DOI : 10.1053/jhep.2003.50208

J. Shim, H. Lee, K. Kim, Y. Lim, Y. Chung et al., Efficacy of entecavir in treatment-na??ve patients with hepatitis B virus-related decompensated cirrhosis, Journal of Hepatology, vol.52, issue.2, pp.176-182, 2010.
DOI : 10.1016/j.jhep.2009.11.007

Y. Liaw, I. Sheen, C. Lee, U. Akarca, G. Papatheodoridis et al., Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, pp.62-72, 2011.
DOI : 10.1002/hep.23952

G. Papatheodoridis, P. Lampertico, S. Manolakopoulos, and A. Lok, Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review, Journal of Hepatology, vol.53, issue.2, pp.348-356, 2010.
DOI : 10.1016/j.jhep.2010.02.035

W. Chotiyaputta, C. Peterson, F. Ditah, D. Goodwin, and A. Lok, Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B, Journal of Hepatology, vol.54, issue.1, pp.12-18, 2010.
DOI : 10.1016/j.jhep.2010.06.016

M. Hilleret, Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?, Journal of Hepatology, vol.55, issue.6, pp.1467-1472, 2011.
DOI : 10.1016/j.jhep.2011.04.006

E. Donald and M. Morisky, Robin DiMatteob Improving the measurement of selfreported medication nonadherence, J Clin Epidemiol, vol.64, issue.3, pp.255-263, 2011.